Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TREPROSTINIL Cause Systemic lupus erythematosus? 194 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 194 reports of Systemic lupus erythematosus have been filed in association with TREPROSTINIL (TYVASO). This represents 0.2% of all adverse event reports for TREPROSTINIL.

194
Reports of Systemic lupus erythematosus with TREPROSTINIL
0.2%
of all TREPROSTINIL reports
19
Deaths
118
Hospitalizations

How Dangerous Is Systemic lupus erythematosus From TREPROSTINIL?

Of the 194 reports, 19 (9.8%) resulted in death, 118 (60.8%) required hospitalization, and 4 (2.1%) were considered life-threatening.

Is Systemic lupus erythematosus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 194 reports have been filed with the FAERS database.

What Other Side Effects Does TREPROSTINIL Cause?

Dyspnoea (16,348) Headache (14,051) Diarrhoea (11,335) Nausea (10,320) Cough (8,945) Fatigue (7,440) Dizziness (7,405) Infusion site pain (5,169) Vomiting (5,097) Death (4,764)

What Other Drugs Cause Systemic lupus erythematosus?

ADALIMUMAB (11,880) METHOTREXATE (9,350) INFLIXIMAB (9,071) ABATACEPT (8,944) HYDROXYCHLOROQUINE (8,867) RITUXIMAB (8,819) PREDNISONE (8,799) LEFLUNOMIDE (8,669) TOCILIZUMAB (8,656) FOLIC ACID (8,360)

Which TREPROSTINIL Alternatives Have Lower Systemic lupus erythematosus Risk?

TREPROSTINIL vs TREPROSTINIL DIOLAMINE TREPROSTINIL vs TRETINOIN TREPROSTINIL vs TRIAMCINOLONE TREPROSTINIL vs TRIAMCINOLONE ACETONIDE TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE

Related Pages

TREPROSTINIL Full Profile All Systemic lupus erythematosus Reports All Drugs Causing Systemic lupus erythematosus TREPROSTINIL Demographics